SCHEMBL16184012

SCHEMBL16184012

COc1cc(-c2ccccc2F)cc2c(N3CCc4cc(Cl)ccc43)nc(-c3cccnc3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ PTGER2 P43116 1/20 0.40
▸ HTR2A P28223 5/20 0.37
▸ HTR2C P28335 5/20 0.37
▸ HTR2B P41595 4/20 0.37
▸ PDE10A Q9Y233 2/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ PDE5A O76074 1/20 0.36
▸ PDE11A Q9HCR9 1/20 0.36
▸ CYP1A2 P05177 2/20 0.35
▸ CYP11B2 P19099 5/20 0.35
▸ CYP11B1 P15538 3/20 0.35
▸ PDE7A Q13946 1/20 0.35
▸ PDE3A Q14432 1/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP19A1 P11511 1/20 0.35
▸ GBA1 P04062 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184015 0.94 ALDH1A1 (0.41) ALDH1A1GAAMAPTPTGER2HTR2A
SCHEMBL16184014 0.89 MAPT (0.42) ALDH1A1GAAMAPTPTGER2HTR2A
SCHEMBL16184013 0.88 MAPT (0.42) ALDH1A1GAAMAPTPTGER2HTR2A
SCHEMBL16183995 0.86 ALDH1A1 (0.45) ALDH1A1GAAMAPTPTGER2HTR2A
SCHEMBL16183413 0.83 CYP11B2 (0.40) ALDH1A1GAAMAPTHTR2AHTR2C
SCHEMBL16183389 0.82 GBA1 (0.44) ALDH1A1GAAMAPTPDE5ACYP1A2
SCHEMBL16184701 0.82 MAPT (0.46) ALDH1A1GAAMAPTPDE10APDE2A
SCHEMBL16184698 0.81 CYP1A2 (0.55) ALDH1A1GAAMAPTCYP1A2CYP3A4
SCHEMBL16184053 0.81 MAPT (0.48) ALDH1A1GAAMAPTPDE10APDE2A
SCHEMBL16184690 0.81 ALDH1A1 (0.51) ALDH1A1GAAMAPTPDE10APDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB ALDH1A1 1687/4885GAA 406/4885MAPT 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback